📰 Cell Therapy Development News
Page 2 - Cell Therapy Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cell Therapy Development. Real-time updates on events, politics, business and more.
May 30, 2023
Pivotal trials TRANSCEND FL and TRANSCEND NHL 001 continue to underscore the transformative potential of Breyanzi and its clinically meaningful benefit across the broadest array of B-cell... | May 30, 2023
May 30, 2023
Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.
May 25, 2023
TRANSCEND CLL 004 is the first pivotal multicenter trial to evaluate a CAR T cell therapy in heavily pre-treated patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic... | May 25, 2023
May 4, 2023
The therapy had a clinically meaningful response in patients with relapsed or refractory (R/R) follicular lymphoma and R/R mantle cell lymphoma.
May 3, 2023
CAR T-cell therapy Breyanzi has been approved by the European Commission (EC) based on significant results from a lymphoma Phase III trial.
May 3, 2023
The European Commission has approved lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
May 1, 2023
With these results, Breyanzi has now demonstrated clinically meaningful benefit across the broadest array of B-cell malignancies of any CD19-directed CAR T cell therapy, underscoring the... | May 1, 2023
May 1, 2023
Lisocabtagene maraleucel elicited statistically significant and clinically meaningful responses in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma, meeting the primary end point of the phase 2 TRANSCEND FL and phase 1 TRANSCEND NHL 001 trials, respectively.
April 17, 2023
U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023 European Medicines Agency has... | April 17, 2023
April 17, 2023
U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023European Medicines Agency has validated Bristol Myers Squibb’s Type II variation application for AbecmaBristol Myers Squibb’s supplemental New Drug Applicatio...